SCHEMBL21591528

SCHEMBL21591528

Cc1ccc2c(=O)c(CCl)c(C)oc2c1C

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PON1 P27169 1/20 0.55
▸ NQO1 P15559 1/20 0.48
▸ GLA P06280 1/20 0.45
▸ STING1 Q86WV6 1/20 0.45
▸ MCL1 Q07820 1/20 0.41
▸ KMT2A Q03164 6/20 0.38
▸ MEN1 O00255 5/20 0.38
▸ NPC1 O15118 4/20 0.37
▸ RAB9A P51151 4/20 0.37
▸ ATM Q13315 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ CSNK2A2 P19784 1/20 0.36
▸ CSNK2B P67870 1/20 0.36
▸ CSNK2A1 P68400 1/20 0.36
▸ ESR1 P03372 1/20 0.36
▸ ESR2 Q92731 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21591455 0.71 PON1 (0.55) PON1NQO1GLASTING1KMT2A
SCHEMBL1161017 0.70 MAOA (0.52) GLAKMT2AMEN1NPC1RAB9A
SCHEMBL9160558 0.70 KDM4E (0.42) GLAMCL1KMT2AMEN1ALDH1A1
SCHEMBL24403682 0.69 GLA (0.49) PON1NQO1GLASTING1MCL1
SCHEMBL1115777 0.69 KDM4E (0.51) PON1GLAMCL1KMT2AMEN1
SCHEMBL13395991 0.68 GLA (0.62) PON1NQO1GLASTING1MCL1
SCHEMBL28469112 0.68 GLA (0.58) PON1NQO1GLASTING1MCL1
SCHEMBL11976504 0.68 MCL1 (0.55) PON1NQO1GLASTING1MCL1
SCHEMBL1324122 0.67 PTGS2 (0.57) GLASTING1KMT2AMEN1NPC1
SCHEMBL29398254 0.67 PTGS2 (0.57) GLASTING1KMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
EP-3807264-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2021-04-21 — — EP disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS PON1 4869/4885NQO1 598/4885GLA 3166/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS PON1 4869/4885NQO1 598/4885GLA 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback